Dr Ben Herbert

Dr Ben Herbert leads the Translational Regenerative Medicine research group at the Kolling Institute based at Royal North Shore Hospital. 

Dr Herbert has 25 years of experience in technology development and commercialisation and has co-founded two ASX listed companies in the biotech/healthcare industry. He has broad experience in securing investment for companies in the biotech/healthcare industry and a track record of creating, protecting, and commercialising intellectual property. He has developed and commercialised biotechnology products with multinational partners, such as Bio-Rad and Sigma-Aldrich, and his co-founded companies – Proteome Systems, Regeneus and Sangui Bio.

In 1999, he co-founded the biotechnology company Proteome Systems, where he served full time as Head of Sample Preparation until 2006. He played an active role in establishing and managing Proteome Systems IP portfolio.

In 2007 Ben was a co-founder of Regeneus Ltd, a regenerative medicine company that has developed and commercialised stem cell therapies using adipose derived cells. Ben served as a non-executive Director of Regeneus from startup through ASX listing in 2013 and left the Board to pursue the opportunities that became Sangui Bio in late 2014. He maintains strong connections to Regeneus Ltd.

Intellectual Property

Dr Herbert has 8 granted patents on proteomics technology (US, EU, AU) owned by Macquarie University and Proteome Systems. He has developed IP (patents pending) with Regeneus on inflammatory biomarkers to monitor disease progression and the effect of mesenchymal stem cell therapy. He is also an inventor on three patent applications covering the Sangui Bio discoveries. Dr Herbert has significant experience with assessment of the IP landscape in various research areas; including instrumentation, consumables and biologicals, patent drafting/filing, due diligence, and patent challenges.

Research Impact and Contribution

Ben Herbert has 36 years of experience in protein chemistry, sample preparation, fractionation, and proteomics. He has gained international recognition as one of key innovators in sample preparation, fractionation and the use of proteomics. He has 74 research and review papers and has contributed chapters, by invitation, to six books, most recently including two book chapters on state-of-the-art proteomics technology. His research papers and chapters have been cited 7100 times and his H-index measurement of research impact is 39. Dr Herbert has supervised 9 PhD students to completion and currently co-supervises 1 PhD student.